We are working on a world where autism is no longer an obstacle
Kuzani is developing novel medicines that can be routinely prescribed to and used by children to treat the underlying basis of autism during their key developmental years.
Kuzani is developing novel medicines that can be routinely prescribed to and used by children to treat the underlying basis of autism during their key developmental years.
Kuzani is a clinical stage biotechnology company formed specifically to advance novel medicines for the treatment of the core symptoms of autism in children. The company’s team is composed of experienced industry professionals and healthcare investors and is collaborating with Dr. Robert Naviaux at UC San Diego to build upon his important initial clinical work in children with autism.
1 in 54 children will be diagnosed
with autism in 2020*
* CDC, 2020
Kuzani’s mission is to advance its novel anti-purinergic medicines and conduct well-controlled clinical development program that meets the standards of scientific rigor of physicians, FDA, regulatory agencies, and parents for the treatment of pediatric Autism.
In children with ASD, Anxiety disorders are 3x more prevalent and ADHD is 10x more prevalent*
Kuzani is working with leading pediatricians, neurologists, clinical sites and thought leaders to design and execute robust clinical studies that can rapidly determine the safety and efficacy of our novel medicines in order to benefit children and families impacted by autism.
of children diagnosed with autism (ASD) do not have intellectual disability.
* CDC
Kuzani’s team has decades of experience in drug development, chemistry and manufacturing, clinical study design, and successful submissions to the FDA.
CEO
Brent is CEO and founder of Kuzani. He has over 20 years experience in therapeutic and medical device development. Previously, he worked as part of the investment team and The Morningside Group and as the CEO & founder of Cognoa, Inc., a digital therapeutic company developing the first diagnostic for pediatricians to diagnose autism.
Head of Development
Michael Glembourtt, BS, MBA; more than 30 years of drug development experience in the biotech and pharmaceutical industry. Leadership roles on 15+ novel drug development teams including two successful NDA programs.
Chief Medical Officer
Dr. Megerian has over 20 years designing and executing clinical trials and leading clinical development programs. He trained in the Medical Scientist Training Program at Northwestern University, earning MD, PhD in Neuroscience (1993). He did his Pediatrics training at Boston City Hospital and his Neurology Training at the Harvard-Longwood Program, completing residency in 1998 and a Fellowship in Behavioral Child Neurology at Boston Children’s Hospital in 2000.
Dr. Megerian was Attending Neurologist in Behavioral Child Neurology at Boston Children’s Hospital and at MassGeneral For Children, North Shore Hospital, where he ran autism programs for Neurology and was Instructor in Neurology at Harvard University Medical School (1999-2015). Dr. Megerian continues to see patients a few hours each month, specializing in treating children with autism.
Head of CMC
Mike Spellman oversees Kuzani’s CMC activities. He has over 30 years of drug development experience, either as an independent consultant or within companies such as Genentech, Coulter Pharmaceuticals, Millennium and Dynogen.
Head of Regulatory Affairs
Ms. Gottfried has successfully led pharmaceutical, biologic, and medical device product development and pre-commercialization teams over the past 25+ years to over 200 marketing authorizations in the US and Internationally. She is recognized as an expert provider of high-value regulated systems and streamlined regulatory processes that translate to corporate value and monetization.
Director of Clinical Operations
Ms. Nguyen has 17+ years of experience in R&D and clinical research operations in the pharmaceutical industry. Ms. Nguyen previously held key roles in clinical operations for Prometheus, Spectrum Pharmaceuticals and Pfizer, as well as in R&D project management at Valeant Pharmaceuticals.
During her tenure at Avanir Pharmaceuticals, from 2012 to 2014, Ms. Nguyen managed a critical Phase 2 study with positive outcomes. Once Avanir Pharmaceuticals was acquired by Otsuka Holdings in 2015, Ms. Nguyen was placed in the lead role as director for their flagship clinical program consisting of 4 large U.S. and global Phase 3 trials. Ms. Nguyen holds a BS in Chemistry from Allegheny College.
Let us know if you would like to keep informed about Kuzani’s study and progress
